强心甙治疗心衰已有200多年的历史,但在临床实践中由于毒性反应较多,而且还常常遇到一些强心甙难以救治的病例,因此促使人们研究更有效的强心药或其他有效的治疗药物。改造现有的强心甙药物的结构和寻找非甙类强心药现已成为重点研究内容之一,因此相继出现了半合成心甙类药物甲基地高辛和非甙类强心药氨联吡啶酮(Amrinone),为心衰治疗开辟了新的途径。除强心药以外,从60年代后期又开始广泛地研究了治疗心衰的减负荷疗法,如 Cardiac glycopeptide treatment of heart failure has a history of more than 200 years, but in clinical practice due to more toxic reactions, but also often encountered some cases of cardiac glycosides difficult to cure, prompting people to study more effective cardiac or other Effective treatment medicine. The transformation of the structure of the existing cardiac glycoside drugs and the search for non-glycosides cardiac medicine has now become one of the key research, so have appeared semisynthetic glycosides methyl digoxin and non-glycosaminogamy Anemia Amrinone opens up new avenues for the treatment of heart failure. In addition to cardiac drugs, from the late 1960s began to extensively studied the treatment of heart failure load-lowering therapy, such as